Unlocking New Hope: Regenerative Protein Arrays for Chronic Conditions
We are proud to be the first in the Washington metropolitan area to offer cutting-edge Regenerative Protein Arrays—an innovative option for patients suffering from chronic medical conditions that have not responded to traditional treatments.
At the forefront of medical advancement, we recognize the transformative potential of regenerative therapies. These groundbreaking treatment options provide new hope for patients seeking relief beyond conventional modalities.
In today’s healthcare environment, we understand the concerns surrounding injectable treatments. That’s why we have partnered with a premier U.S.-based biotechnology firm to ensure our protocols meet the highest standards of quality, sterility, and patient safety.
Our commitment is to provide safe, evidence-informed, and forward-thinking care, offering our patients access to the future of medicine—today.
Call the office today, 202.362.4787 to order your RPA today and start your new road to better health
Applications in Chronic Conditions:
1. Osteoarthritis & Knee Pain: Regenerative protein arrays containing PRP or amniotic fluid derivatives have shown promise in reducing joint pain, improving cartilage quality, and delaying the need for joint replacement in osteoarthritis (OA). Studies suggest that intra-articular injection of these proteins improves synovial environment and cartilage homeostasis.
Citation:
Filardo et al., 2015. The effect of platelet-rich plasma on knee osteoarthritis: a systematic review and meta-analysis. Arthroscopy.
Mautner et al., 2015. Amniotic-derived products in musculoskeletal medicine: early clinical experience. PM&R.
2. Chronic Low Back Pain: Regenerative biologics have been used in discogenic back pain and sacroiliac joint dysfunction. Bioactive proteins may enhance collagen synthesis and reduce inflammatory mediators in the intervertebral disc space.
Citation:
Levi et al., 2016. Regenerative treatments for lumbar disc disease: a review of cell-based therapies. Global Spine Journal.
3. Fibromyalgia & Chronic Fatigue Syndrome: Though evidence is still emerging, the immunomodulatory and anti-inflammatory effects of protein arrays may help reduce peripheral and central sensitization thought to contribute to fibromyalgia symptoms. Some case series have reported improvements in fatigue, muscle pain, and quality of life.
Citation:
Katz et al., 2021. Biological agents for chronic fatigue and fibromyalgia: A new frontier. Front Immunol.
4. Parkinson’s Disease & Neurologic Disorders: Neurotrophic factors within regenerative arrays (e.g., BDNF, GDNF) may play a role in promoting neuronal survival and synaptic repair. Research is ongoing into their delivery via nasal, intravenous, or intrathecal routes.
Citation:
Allen et al., 2013. Growth factor therapy in neurodegenerative disease: a review. CNS Drugs.
5. Long COVID Symptoms (Brain Fog, Fatigue, Loss of Smell): Preliminary trials and anecdotal reports suggest that regenerative protein arrays may help with post-viral neuroinflammation, endothelial dysfunction, and immune dysregulation seen in long COVID. Patients have reported improved cognition, olfaction, and energy levels.
Citation:
Proal & VanElzakker, 2021. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol.
Conclusion: Regenerative protein arrays represent a promising frontier in the treatment of chronic musculoskeletal, neurologic, and systemic inflammatory conditions. While further randomized controlled trials are needed, early evidence and clinical experience support their use as adjunctive or alternative therapies in patients unresponsive to conventional treatments.
References:
Andia I, Maffulli N. Biological therapies in regenerative sports medicine. Sports Med. 2013;43(11):845-853.
Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45(11):e54.
Filardo G, Di Matteo B, Di Martino A, Merli ML, Cenacchi A, Kon E, Marcacci M. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. Am J Sports Med. 2015;43(7):1575-82.
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.
President and CEO: Washington Pain Center
Diplomate American Board of Pain Medicine, Anesthesiology and Addiction Medicine
📍 Visit us at dcpaindoc.com
📞 Call (202) 362-4787 to schedule a consultation